133 related articles for article (PubMed ID: 38698539)
1. Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform.
Chelle P; Hajducek D; Thibaudeau K; Hobson N; Iorio A; Shapiro A; Edginton A
Haemophilia; 2024 May; ():. PubMed ID: 38698539
[TBL] [Abstract][Full Text] [Related]
2. Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).
McEneny-King A; Foster G; Iorio A; Edginton AN
JMIR Res Protoc; 2016 Dec; 5(4):e232. PubMed ID: 27927609
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project.
Hajducek DM; Chelle P; Hermans C; Iorio A; McEneny-King A; Yu J; Edginton A
Haemophilia; 2020 May; 26(3):384-400. PubMed ID: 32281726
[TBL] [Abstract][Full Text] [Related]
4. External qualification of the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data.
Chelle P; Hajducek D; Mahdi M; Young S; Iorio A; Silvertown J; Edginton A
Res Pract Thromb Haemost; 2021 Oct; 5(7):e12599. PubMed ID: 34761154
[TBL] [Abstract][Full Text] [Related]
5. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
Chelle P; Yeung CHT; Bonanad S; Morales Muñoz JC; Ozelo MC; Megías Vericat JE; Iorio A; Spears J; Mir R; Edginton A
J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):427-438. PubMed ID: 31115857
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate
Chelle P; Yeung CHT; Croteau SE; Lissick J; Balasa V; Ashburner C; Park YS; Bonanad S; Megías-Vericat JE; Nagao A; Wynn T; Corrales-Medina F; Tran H; Sharathkumar A; Chitlur M; Sarmiento S; Edginton A; Iorio A
Clin Pharmacokinet; 2020 Feb; 59(2):245-256. PubMed ID: 31435896
[TBL] [Abstract][Full Text] [Related]
7. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.
Iorio A; Keepanasseril A; Foster G; Navarro-Ruan T; McEneny-King A; Edginton AN; Thabane L;
JMIR Res Protoc; 2016 Dec; 5(4):e239. PubMed ID: 27977390
[TBL] [Abstract][Full Text] [Related]
8. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
Arvanitakis A; Berntorp E; Astermark J
Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users.
McEneny-King A; Yeung CH; Edginton AN; Iorio A; Croteau SE
Haemophilia; 2020 Jan; 26(1):56-63. PubMed ID: 31742831
[TBL] [Abstract][Full Text] [Related]
10. A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates.
Chelle P; Iorio A; Edginton AN
J Thromb Haemost; 2022 Sep; 20(9):2012-2021. PubMed ID: 35753074
[TBL] [Abstract][Full Text] [Related]
11. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
Yu JK; Iorio A; Edginton AN
Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
[TBL] [Abstract][Full Text] [Related]
12. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).
Goedhart TMHJ; Bukkems LH; Coppens M; Fijnvandraat KJ; Schols SEM; Schutgens REG; Eikenboom J; Heubel-Moenen FCJI; Ypma PF; Nieuwenhuizen L; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH
TH Open; 2022 Jan; 6(1):e60-e69. PubMed ID: 35280975
[TBL] [Abstract][Full Text] [Related]
13. Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
Astermark J; Olsson A; Chelle P; Täckström K; Walger M; Magnusson M; Iorio A
Haemophilia; 2021 Jul; 27(4):626-633. PubMed ID: 33966319
[TBL] [Abstract][Full Text] [Related]
14. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients.
Hajducek DM; Chelle P; Iorio A; Iserman E; Edginton AN
Haemophilia; 2024 May; ():. PubMed ID: 38738967
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.
Nagao A; Yeung CHT; Germini F; Suzuki T
Thromb Res; 2019 Jan; 173():79-84. PubMed ID: 30496937
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
[TBL] [Abstract][Full Text] [Related]
17. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A.
Chen Z; Huang K; Li G; Zhen Y; Wu X; Di A; Liu G; Li Z; Alfonso I; Wu R
Pediatr Investig; 2021 Mar; 5(1):38-45. PubMed ID: 33778426
[TBL] [Abstract][Full Text] [Related]
19. Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products.
Teitel J; Sholzberg M; Iorio A
Res Pract Thromb Haemost; 2021 Feb; 5(2):349-355. PubMed ID: 33733034
[TBL] [Abstract][Full Text] [Related]
20. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
